Study examines best sequence of treatments for advanced bowel cancer
NCT ID NCT06137170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at data from 121 people with metastatic colorectal cancer who received two approved treatments—regorafenib and TAS (with or without bevacizumab)—in different orders. Researchers want to see which sequence works better and how long patients live. Since this is an observational study using existing health records, no new treatments or visits are involved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib, TAS (trifluridine/tipiracil), bevacizumab
What this could lead to
If successful, this study could help doctors choose the best order of treatments for people with advanced colorectal cancer, potentially improving survival.
What could go wrong
This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to all patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, France
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Spain